TACSTD2 and lung carcinoma: In lung cancer, Trop2 overexpression has been observed in up to 64% of adenocarcinoma and up to 75% of squamous cell carcinoma NSCLC66,68, and associated with reduced survival69; a potential role in resistance to chemotherapy and CD8+ T-cell apoptosis has also been suggested70.